Repository: UIHistories Project: Board of Trustees Minutes - 1954 [PAGE 1250]

EXTRACTED TEXT FROM PAGE:

1954]

UNIVERSITY OF ILLINOIS

1247

167. Eli Lilly Company, Indianapolis, Indiana: a. $1,671 to the Department of Physiology for a study of synovial membrane permeability, under the direction of Dr. C. I. Reed. b. $2,000 to the Department of Physiology for a study of behavior of plasma proteins in the kidney, under the direction of Dr. A. A. Schiller. c. $5,400 to the Department of Medicine for a study of the effect of drugs and hormones on the production of anti-erythrocytic auto-antibodies and on the degree of resultant hemolysis, under the direction of Dr. William R. Best. 168. Mallinckrodt Chemical Works, St. Louis, Missouri, $10,000 for the renewal of a fellowship in the Department of Pharmacology for one year beginning January 1, 1953, and an addition to the Mallinckrodt Anticonvulsant Fund, both grants being for studies under the supervision of Dr. C. C. Pfeiffer. 169. Miles Laboratories, Chicago, $650 to the Department of Clinical Science for research on pancreatitis, under the direction of Dr. A. C. Ivy. 170. Ohio Chemical and Surgical Equipment Company, Madison, Wisconsin, $700 to the Department of Surgery for a study of isopropyl vinyl ether, under the direction of Dr. M a x S. Sadove. 171. Parke, Davis and Company, Detroit, Michigan, $3,600 to the Department of Biological Chemistry for a study on blood dysorasias, under the direction of Dr. S. B. Binkley. 172. Charles Pfizer and Company, Inc., Brooklyn, New York: a. $12,000 to the Department of Medicine for continuation of investigations of infectious diseases, preventive medicine, and related fields, under the direction of Dr. Harry F. Dowling, for two years beginning September 1, 1952. b. $1,000 for the renewal of scholarships in the College of Medicine. 173. Riker Laboratories, $500 to the Department of Dermatology for a study of the use of silver asboloxane as a fungicidal agent, under the direction of Dr. F. E. Senear. 174. Smith, Kline, and French Laboratories, Philadelphia, Pennsylvania: a. $5,000 for a fellowship under the direction of Dr. C. C. Pfeiffer, Department of Pharmacology, for one year beginning January I, 1953. b. $1,000 for lectures on neurophysiology, under the direction of Dr. R. W . Gerard. 175. R. J. Strasenburgh Company, Rochester, New York, $5,500 to the Department of Clinical Science for a study of the effects of inositol hexanitrate in patients with hypertension, under the direction of Dr. A. C. Ivy, for one year beginning May 1, 1952. 176. Travenol Laboratories, Inc., Morton Grove, $2,500 to the Department of Pharmacology for a study of the analgesic and convulsant effect of pyrogens, under the direction of Dr. C. C. Pfeiffer, for one year beginning January 1, 1952. 177. Winthrop-Stearns, Inc., New York, New York, $500 to the Department of Surgery for investigation of ravocaine with inositol, under the direction of Dr. Max S. Sadove. 178. Mr. Victor S. Yarros, $300 to be added to the Rachelle S. Yarros Scholarship Fund. 179. Louis Bothman Fellowship Memorial Fund, Inc., $1,264.86 for the Louis Bothman fellowship in ocular pathology, under the supervision of Dr. William F . Hughes, Jr. 180. Chandler Research Fund, $16 to the Department of Orthopaedic Surgery for research under the direction of Dr. F. A. Chandler. 181. W . K. Kellogg Foundation, $20,000 to the College of Dentistry for the development of extension postgraduate teaching program. 182. Lakeland Foundation, Chicago: a. $12,429 to the Department of Clinical Science for continuation of a study to attempt to isolate the growth stimulating and inhibiting agents from the liver or intestinal mucosa, under the direction of Dr. A. C. Ivy. b. $1,778 to the Department of Clinical Science for continuation of the cancer diagnostic test, under the direction of Dr. A. C. Ivy. 183. Leukemia Research Foundation, Inc., Chicago, $5,648 to the Department of Anatomy for a study on the influence of the age of the mother on the incidence of spontaneous leukemia in inbred mice, under the direction of Dr. Arthur Kirschbaum, for the period April 1, 1953, through September 30, 1954.